Tradestie Institutional Equity Comparison Engine
CVM vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (3โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs ANRO N/M Fwd P/E
Growth & Margin Winner
ANRO
Op Margin 0.0% vs 0.0% ยท YoY -62.7% vs +0.0%
Momentum & Technical Winner
ANRO
1Y -73.0% vs +107.4% ยท 52W Pos 15% vs 54%
Options & Structure Winner
ANRO
BREAKDOWN (N/A IV) vs BREAKDOWN (8th %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap
$22.5M
1M Return
+15.45%
1Y Return
-72.98%
Forward P/E
23.0x
Unified AI Score
43.5 / 100
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap
$1.2B
1M Return
+10.08%
1Y Return
+107.43%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 15.0
Fund 38.0
Flow 64.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -72.98%
ANRO +107.43%
Spread: +178.65 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CVM TTM Op. Margin: 0.0%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVM vs ANRO. Trailing 12-month operating profitability (CVM 0.0% vs ANRO 0.0%) and valuation multiples (CVM 23.0x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $22.5M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -62.7% | +0.0% | Higher Growth | ANRO |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 15% ($1โ$8) | 54% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 0.45ฮฒ ยท 139% Vol | 2.03ฮฒ ยท 94% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 34.3 / 100 (SELL) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs ANRO Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ANRO
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.